NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









NaDeNo Nanoscience

NaDeNo Nanoscience

Private
TrondheimHealthcare & Life Scienceshttps://nadeno.com/

Last Round

Grant

Feb 17, 2026

Momentum

Top 10%

of companies Caplight tracks

Company Overview

NaDeNo Nanoscience AS is a biotechnology company developing a nanotechnology drug delivery platform designed to enable direct drug delivery and prolonged retention at tumor sites.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Advanced Materials, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

drug delivery platformnanoparticle drug deliverynanomedicinetargeted drug deliverycancer treatmentdrug encapsulationovarian cancerpolymeric nanoparticlescontrolled releasedrug formulationhydrophobic drugsoncologyclinical stage biotechPACA nanoparticles

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NaDeNo Nanoscience Comparables

Compare NaDeNo Nanoscience with similar companies based on industry and business-model similarity.

NaDeNo Nanoscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NanoDrug Delivery GmbH
86%
Cristal Therapeutics
83%
UPyTher B.V.
82%

NaDeNo Nanoscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 17, 2026
SeedJan 27, 2023

Key People

Founding team and executive leadership

Annbjørg Eide Falck

Chief Executive Officer

Executive Team

Yrr Mørch

Chief Technology Officer

Executive Team

NaDeNo Nanoscience Investors

Notable investors and investment history

NaDeNo Nanoscience investors
InvestorRounds
European Innovation Council FundGrant
SINTEF VentureSeed
Farvatn VentureSeed
NOMEAccelerator
EIC FundGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 17, 2026

    $12M grant received from European Innovation Council.

  • Aug 5, 2025

    Proprietary platform technology launched to overcome drug delivery hurdles for hydrophobic drugs.

NaDeNo Nanoscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NaDeNo Nanoscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NaDeNo Nanoscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersTrondheim
Employee Range12
Year Founded2022
Last FundingFeb 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.